Please try another search
Amryt Pharmaceuticals Inc. a biopharmaceutical company, engages in the development and commercialization of therapies for patients with debilitating rare diseases. It markets Juxtapid (lomitapide) capsule, a prescription medicine, used along with diet and other lipid-lowering treatments, including low-density lipoprotein apheresis, homozygous familial hypercholesterolemia, total cholesterol, a protein that carries bad cholesterol in the blood (apolipoprotein B), and non-high-density lipoprotein cholesterol. The company also markets Myalept (metreleptin), a leptin replacement therapy, used with a doctor-recommended diet to treat problems caused by not having enough leptin (leptin deficiency) in people with generalized lipodystrophy. In addition, it is developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. The company was formerly known as Aegerion Pharmaceuticals, Inc. and changed its name to Amryt Pharmaceuticals Inc. in July 2022. Amryt Pharmaceuticals Inc. was incorporated in 2005 and is based in Cambridge, Massachusetts. Amryt Pharmaceuticals Inc. operates as a subsidiary of AMRYT Pharma Holdings Limited
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review